GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qualigen Therapeutics Inc (NAS:QLGN) » Definitions » PB Ratio

QLGN (Qualigen Therapeutics) PB Ratio : (As of Mar. 31, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Qualigen Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-03-31), Qualigen Therapeutics's share price is $3.80. Qualigen Therapeutics's Book Value per Share for the quarter that ended in Sep. 2024 was $-3.91. Hence, Qualigen Therapeutics's PB Ratio of today is .

The historical rank and industry rank for Qualigen Therapeutics's PB Ratio or its related term are showing as below:

During the past 4 years, Qualigen Therapeutics's highest PB Ratio was 4.91. The lowest was 0.06. And the median was 0.93.

QLGN's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.37
* Ranked among companies with meaningful PB Ratio only.

During the past 3 years, the average Book Value Per Share Growth Rate was 38.20% per year.

During the past 4 years, the highest 3-Year average Book Value Per Share Growth Rate of Qualigen Therapeutics was 38.20% per year. The lowest was 38.20% per year. And the median was 38.20% per year.

Back to Basics: PB Ratio


Qualigen Therapeutics PB Ratio Historical Data

The historical data trend for Qualigen Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qualigen Therapeutics PB Ratio Chart

Qualigen Therapeutics Annual Data
Trend Mar20 Dec21 Dec22 Dec23
PB Ratio
- 2.29 0.75 -

Qualigen Therapeutics Quarterly Data
Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Qualigen Therapeutics's PB Ratio

For the Biotechnology subindustry, Qualigen Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qualigen Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Qualigen Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Qualigen Therapeutics's PB Ratio falls into.


;
;

Qualigen Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Qualigen Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2024)
=3.80/-3.907
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Qualigen Therapeutics  (NAS:QLGN) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Qualigen Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Qualigen Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Qualigen Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
5857 Owens Avenue, Suite 300, Carlsbad, CA, USA, 92008
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
Executives
Michael S. Poirier director, officer: Chairman, President and CEO 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Amy S. Broidrick director 1440 VALLE GRANDE, ESCONDIDO CA 92025
Kurt H Kruger director 100 FOXBOROUGH BLVD, SUITE 240, FOXBOROUGH MA 02035
Tariq Arshad officer: SVP/Chief Medical Officer 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Christopher L. Lotz officer: Vice President of Finance, CFO 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 90211
Emery Sidney W Jr director C/O QUALIGEN THERAPEUTICS, INC., 2042 CORTE DEL NOGAL, CARLSBAD CA 92011
Richard A. David director 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Wajdi Abdul-ahad officer: VP, R&D, CSO 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Shishir K. Sinha officer: VP of Operations 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Sekisui Diagnostics, Llc 10 percent owner 1 WALL STREET, BURLINGTON MA 01803
Matthew E Korenberg director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Noah Doyle director C/O RITTER PHARMACEUTICALS INC., 1801 CENTURY PARK EAST, SUITE 1820, LOS ANGELES CA 90096
John W Beck officer: Chief Financial Officer C/O RITTER PHARMACEUTICALS, INC., 1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES CA 90067
Jeffrey S Benjamin officer: VP of Finance 3885 CRESTWOOD PARKWAY, SUITE 550, DULUTH GA 30096
William M. Merino director C/O RITTER PHARMACEUTICALS INC., 1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES CA 90067